click enter text
highlight pipelin unplug call
senior leadership
may host confer call videoconfer format
pipelin unplug seri dr skovronski chief
scientif offic presid lilli research laboratori
gimeno vice presid diabet research clinic investig
bodi note comprehens recap call essenti
full transcript edit clariti
replay call tune addit call may/jun
continu rate peer perform inform
stock cover see march monthli
controversi report us/eu pharma name
trade fundament data
upsid target
report limit sole use client wolf research pleas refer disclosur section locat end
report analyst certif import disclosur disclosur
page
wolf thought would start coupl high-level question benefit listen
mayb remind investor prioriti area compani ideal rank order
term import see biggest opportun highest level excit
dr skovronski hard pick amongst children sinc talk diabet
start biggest area area longest histori
number excit innov talk today oncolog big busi unit fuel
loxo oncolog acquisit excit prospect immunolog import area
us lot progress coupl market product come talk today
neurosci area probabl face largest unmet medic need also
challeng area work continu work hard alzheim diseas area
pain within neurosci anoth big unmet medic need four area got
excit thing tim
wolf last year ask similar question talk diseas area mention
coupl thing earli initi realli heard brought last
month mention interest cell-bas therapi well gene therapi
latest think two
dr skovronski think lilli histori obvious player small molecul
long time earli mover biotechnolog lost thread littl
huge part portfolio half innov biotech product histor
stray small molecul biotech molecul antibodi peptid protein last coupl year
start expand activ program rna particularli sirna least one
program cell-bas therapi diabet preclin advanc quickli toward patient
think new modal like rna therapeut hold enorm potenti patient compani like us
question make technolog scale help larg number patient big diseas
work gene therapi bit differ gene therapi modal may best suit toward smaller
popul smaller diseas activ particularli neurosci among
therapeut area see lot activ gene therapi someth eye
continu evalu intern gene therapi program yet
wolf want shift therapeut shot goal go hold
talk instead ask covid impact conduct clinic trial lilli
look variou program clinicaltri gov fulli suspend yet other continu
wonder decid trial suspend keep go look across
compani everi compani take approach seem like lot offici
suspend trial gov
dr skovronski decid take proactiv approach press releas base
decis halt new enrol across portfolio allow certain trial enrol except
process default enrol new patient took default postur
worri abil support trial worri burden
investig hospit felt prioriti anticip situat get wors
page
type except made molecul basi geographi basi molecul basi
particularli oncolog lifesav medic high likelihood work may
avail patient except clinic trial thing like said worth kept
go except made geographi continu expand initi even
shut clinic trial across world china emerg coronaviru site china allow
continu enrol patient time ad countri initi asia europ
clinicaltri gov may lag behind littl bit trial list partial enrol mean site
geographi molecul thought benefit-risk made sens continu enrol
recent last week two countri europ come on-line permit
clinic trial resum enrol us situat good burden coronaviru remain
high get lot interest investig enrol patient import part work
want resum come process evalu site us site site basi
know big countri lot heterogen hope resum enrol us
come week month certainli
said question know enrol resum pre kind rate
go longer period slightli slower enrol think soon say us europ
see optimist right see bolu patient wait come clinic trial
lot pent demand investig short term feel pretti good thing feel good
discontinu rate across portfolio watch miss visit time window visit
seen worrisom signal compar histor norm like term
patient on-going clinic trial everi day goe feel confid abl
obtain high qualiti data lock databas clean data roughli schedul get high qualiti
result great seen continu execut regul person
concern regul would overwhelm abl interact
abl deal therapeut area case pleas
interact fda regul around world flexibl show need make
chang on-going studi gener minor analysi plan account
continu busi less normal even though regul mainli work home
wolf think spend think rule thumb phase drive bu
period trial suspend like show number let say
know guy given offici guidanc imagin go detriment
dr skovronski think right way think phase three trial biggest chunk
spend challeng calcul save bulk spend trial alreadi fulli
enrol follow patient save think given month quarter
much save delay enrol lot expens keep trial go mayb
end year trial ramp year full enrol burn certain amount money
month might get push month two could littl save trial
major spend trial current enrol term save new
enrol offset term invest make therapeut program
ramp comment profil rest year guidanc
context
wolf let shift specif diseas categori start diabet arguabl import
area lilli given make total compani sale thought would jump straight
tirzepatid weekli gip/glp dual agonist get first phase read year think
page
perhap biggest binari event compani consensu alreadi built
lilli model check day ago consensu product approach
distant year big contribut gener see sell side pharma model
unapprov product phase program consist studi youv previous guid
submiss recount listen show phase one trial publish
patient week durat four differ dose tirzepatid placebo arm
trulic compar arm posit much stronger blood sugar control great weight loss
potenti trade toler primarili thing like gi vomit diarrhea
attempt address lower slower dose titrat help guess
like drug balanc efficaci toler safeti let start
timelin program clintrial gov say two trial report later
tri figur get top line press releas full data present perhap ada
dr skovronski mayb start talk scienc reason confid
said lot differ thing mayb start analyst forecast assum probabl adjust
forecast tie comment big outcom sure binari outcom sens
level confid phase data suggest see term efficaci
think gradat respons depend safeti everyon alway ask
interest talk second say timelin look good trial essenti
fulli enrol went situat impact enrol trial progress well
someth watch close point one import therapeut program
one largest therapeut program type ii diabet program proce pace timelin
previous commun delay unfortun next indic obes see
larg opportun great efficaci nash somewhat delay hope make
lost time littl want talk came titrat
scheme confid behind
dr gimeno one thing realiz ph studi studi optim titrat regimen
conduct separ titrat studi publish explor differ titrat algorithm base
two studi conduct quit bit model came titrat paradigm use
phase plan use titrat paradigm obes nash program big
surpris start low dose slowli titrat see better toler consist across
class interest safeti profil benign consist know
class seen addit safeti question emerg feel good program
point time think excit tirzepatid efficaci lower kg weight loss
period number seen molecul think big
contribut gip efficaci big effort preclin clinic side
understand mechan action one emerg piec like import contribut adipos
tissu weight independ insulin sensit see preclin model
analysi clinic data date think translat addit benefit outcom side
wolf time data go see go see full set data
anyth press releas top line result
dr skovronski fulli work exactli disclos alway trade
want disclos anyth materi import sharehold hand want
jeopard full scientif discuss usual conserv compani term
disclos top line mean give mani detail other may exampl
need give littl know kevin want comment specif charg
page
kevin hern think typic comment press releas tactic ahead time think said
appropri look data make sure materi standpoint transpar
commun sharehold guid press releas top line
dr skovronski one new thing happen sinc start trial give littl bit
confid new dose trulic similar situat phase
certain rate gi side effect increas dose work would translat
phase appli kind model pk analysi look time onset side effect think
pretti much nail predict saw differ drug similar type predict
make feel confid phase phase predict hold tirzepatid
dr gimeno one space lot experi would agre think
piec four differ studi point direct tirzepatid quit confid
see good result
wolf question choic compar certain trial trial
compar trulic dulaglutid trial type ii diabet report march
wonder guy chose trulic compar oppos competitor
ozemp avail time trial start choic would suggest mayb
intent switch cannib strategi intent mayb get unintent
cannib wonder chose trulic compar ozemp know novo ran
studi compar ozemp trulic show ozemp effect strike odd
would go product
dr gimeno time start earli clinic trial phase two studi semaglutid
avail could includ ozemp head head studi ozemp phase
program interest high dose dulaglutid data receiv compar
ozemp speak import titrat paradigm import push dose
compar dulaglutid trulic know trulic well plan cardiovascular
outcom studi compar effect studi trulic think could import
product point time wait data come
dr skovronski head head studi semaglutid look phase data think
reason confid superior semaglutid term cvot studi thought hard
whether go standard care competitor think compar trulic make lot
sens given size popul enrol rewind studi trulic know lot
cardiovascular benefit drug broad popul think question physician want answer
compar trulic give import data physician cardiovascular benefit
dr gimeno one addit comment comparison semaglutid plan initi mechan
action studi semaglutid activ compar tri teas differ
wolf compar tirzepatid ozemp least one compar
trial brought cardiovascular outcom trial want switch cardiovascular safeti
sure gotten theoret question recent month cardiovascular
safeti back newer scienc show gip level seem correl higher risk
cardiovascular diseas popul studi random trial also appear
page
gip receptor cardiovascular tissu one scientif paper
author postul gip/glp co-agonist may caus weight loss may lead
less cardiovascular protect concern heard client segu
brought cardiovascular outcom trial look everi prior cardiovascular
outcom trial placebo compar trial go trulic
activ compar unusu one question choos activ
compar advis regulatori agenc done posit strength
show beat
dr skovronski dont comment specif regul interact sure idea
someth want think right question physician right trial highli confid
data would say idea head head cvot leadership posit take think like
becom standard show new innov stack everi cvot
patient allow standard care variabl make result littl difficult
interpret activ compar specifi lot data quit help interpret
data want add comment gip paper
dr gimeno one thing keep mind correl associ studi compar
endogen gip level cardiovascular risk lot thing regul endogen gip level
look preclin clinic data tirzepatid cardiovascular safeti signal whatsoev fact
present lipid data phase two studi see improv pretti much
cardiovascular risk factor apob triglycerid see insulin sensit signific weight
loss point toward cardiovascular benefit studi take consider
believ signific data indic increas cardiovascular risk
wolf base timelin file emb belief need
cardiovascular outcom result dossier
dr gimeno outcom studi go well beyond initi file typic space
de-risk cardiovascular safeti signal meta-analysi plan
dr skovronski yeah typic hurdl
wolf probabl answer question sinc incept larg phase program
chang dsmb monitor term extra cardiovascular event
endpoint data collect anyth cardiovascular light academ talk
gip possibl advers impact cardiovascular system
dr skovronski right start comment thing like sometim
program could chang know kind stuff come unless someth
pretti signific tri much possibl maintain blind limit flow inform like said
thing watch across portfolio miss studi visit discontinu
clinic trial across portfolio quit pleas realli get dsmb data
ask
wolf get wrong big number model tirzepatid thought phase trial
result amaz task ask hard questionsso let ask
coupl hard question one weight loss ask question last year call
well result phase great realli stood two higher dose
page
mg mg patient continu weight loss way end trial
week half year beg question happen year worth
dose two year worth dose could patient much weight loss get
sort metabol disturb nutrit deficit guess alway back use drug
go lower dose think magnitud weight loss possibl
liabil might physiolog bodi
dr gimeno chuckl excit convers may drug
efficaci start think could much weight loss point time depend
mechan weight loss still think influenc normal weight regulatori mechan
see plateau peopl reach normal bodi weight excit within six-month studi trajectori
still go keep mind mani peopl space lose quit bit bariatr surgeri
see weight loss benchmark us speed lose weight also import
want weight loss fast like tirzepatid interest see whether
plateau plateau need start switch percent weight loss peopl reach
normal bodi weight like way think glucos unexplor scientif area
never drug worri
dr skovronski md health benefit weight loss go signific think know
current situat illustr one major risk factor mortal obes look
forward see kind health benefit drive drug like tirzepatid
wolf weight loss central mediat phenomenon target portion brain
control appetit yet know
dr gimeno know sure know strong effect food intak think lot
central mediat may compon energi expenditur see preclin
process map pathway within brain public last year demonstr activ
gip-receptor contain neuron inhibit food intak anim interest gip
receptor neuron talk think turn primarili central mediat phenomenon
wolf anoth topic brought past neutral antibodi tirzepatid rel
glp except exenatide/byetta lli gen quit high think
patient tirzepatid antidrug antibodi ada neutral antidrug
antibodi contrast trulic around ozemp around think trace back
glp backbon use exenatid literatur real world experi
exenatid lot ada attenu glycem effect current think
ada tirzepatid chronic dose whether could attenu glycem effect
dr gimeno quick correct backbon gip backbon compon exenatid
start map antidrug antibodi map molecul clear cut
may expect necessarili exenatid section across studi see roughli incid
antidrug antibodi see tide actual low seen effect efficaci
pharmacokinet inject site reaction advers event date see instanc
neutral antibodi could argu assay cutoff concern signal
someth continu monitor close
page
wolf shift minut earli stage incretin initi sever one look
like anoth gip/glp compound back-up molecul differ tirzepatid
differ glp non-exenatid backbon design get away ada issu
dr gimeno tri design molecul similar tirzepatid possibl tri accomplish
molecul optim oral deliveri primari goal molecul driver potenc
think oral peptid deliveri would like molecul efficaci lower dose compar
tirzepatid also optim stabil gastrointestin fluid compat variou formul
could potenti use oral deliveri driver project look immunogen
primari driver oral deliveri
wolf let finish coupl question obes run phase trial
obes trulic tirzepatid experi thu far tirzepatid non-
diabet obes patient mean patient euglycem think obes trial
still see impact blood sugar tirzepatid differ drug wonder
may play non-diabet obes patient
dr gimeno lot non-diabet obes patient pre-diabet insulin resist fast
glucos continu paramet ye would expect see benefici effect drove us take
tirzepatid obes popul weight loss saw diabet popul weight loss usual
becom pronounc context obes trial felt import benefit need
bring patient also know obes underli driver type two diabet opportun
impact progress diabet overal cardiovascular outcom also big problem
wolf move alzheim separ discuss want ask type diabet
alzheim diseas would love get thought novo nordisk chase
ph elad studi patient read soon fact would
thought would heard talk drug cross blood brain
barrier trulic high-level thought alzheim
dr gimeno agre look elad readout well look forward see want
comment drug cross blood brain barrier incretin isol peptid extent go
littl bit deeper brain enter deep brain region appreci amount want
see alzheim diseas effect see probabl due secondari effect metabol
improv cardiovascular system nice preclin data gip/glp molecul
also molecul suggest benefit alzheim wonder whether lot due import
metabol improv interest see play context clinic studi
want comment
dr skovronski agre think cardiovascular outcom studi teach us
import outcom benefit certainli relat vascular diseas stroke cours
studi measur big stroke clinic signific one know micro infarct dementia
contributor clinic cours mani patient alzheim stop big stroke stop
small stroke pretti straightforward hypothesi drug could benefit think
jump drug go clear amyloid plaqu inhibit tangl scienc littl harder
hand-wav sort bet would say modest
effect cognit health metabol cardiovascular effect said rather direct
page
patholog certainli good healthi overal context alzheim diseas know
epidemiolog studi weight loss exercis thing like go help
wolf want spend minut oral incretin product earli develop
think phase point oral exampl gip/glp back-up
said oral clear oral inject
dr gimeno gip/glp back-up studi complet subcutan administr goal
dose studi demonstr pk pd properti anticip move forward oral formul
later year also non-peptid agonist select agonist phase clinic
test complet sad mad healthi volunt get readi test type two
diabet patient molecul similar tradit small molecul versu oral administ
peptid advantag would expect see less food effect better cost
structur molecul licens chugai gener phase one molecul think
see lot data ada next year
wolf shift neurosci guess area near dear heart given
background start alzheim diseas think lilli compani still all-in full-
bore ahead sinc last call addit event play exampl
confluenc event around engag emerg readout dian-tu select
dataset gantenerumab open-label extens updat view alzheim
space energi level within organ today versu one year ago unchang
dr skovronski bit roller coaster definit littl bit lower littl bit higher
watch aducanumab read import piec data somewhat difficult interpret
look across aducanumab well gantenerumab data dian data
eisai data think grow bodi evid impact amyloid effect
think best studi rather luckiest studi luckiest subgroup luckiest dose mayb
look big take view look across drug across trial across dose
across end point get feel size benefit one challeng drug
variabl abil lower plaqu variabl time cours aducanumab probabl one better one
test hypothesi increas amyloid reduct even get patient complet
clear amyloid per imag faster could bigger effect trial test
antibodi donanemab look forward get data initi aducanumab look like
neg said reason carri trial confid lower plaqu
aducanumab need retest level plaqu lower ad futil analysi would
stop trial unless significantli higher level plaqu reduct seen data
clear hurdl last year make confid great plaqu lower lower plaqu
bigger effect abl see data look forward get phase two data
come end year probabl abl top line earli next year
wolf may reluct answer question someon know space
look aducanumab play enough data view get
approv reason ask investor fenc view probabl
success probabl less talk kol divid mayb middl
page
real data hawk apprehens clinic guy say hey need therapi
land
dr skovronski know sort regul question regul accept
approv look bar past typic across therapeut area level
data clear regulatori hurdl howev thing might littl differ standard may
chang regul may consid weight evid across number differ trial push right
direct regul may consid signific unmet medic need unknown total agre
call data hawk say go listen context typic
regulatori requir approv meet think clear watch
eagerli anyon bar move work agenc make sure appli consist
respect program appli respons want make sure right amount
data program come patient
wolf recent initi coverag link larg cap biotech link
research conclud fda may slow-walk applic want imag data
new embark studi want shift topic imag amyloid imag tau
imag slow progress newer data show interest stuff tau
imag struck aducanumab almost tau imag data serum tau
level background talk current think amyloid imag tau
imag interfac clinic trial perspect also real-world
perspect get approv therapeut role tau imag
flortaucipir wait fda approv anyon know space guess guy
dr skovronski yeah follow close collabor across industri make imag agent
avail help provid expertis interpret result appli across suit biomark
imag also csf plasma flortaucipir fda look action fda
soon excit could wide avail approv tau imag agent think facilit
research like first amyloid imag agent approv fda great futur
situat aducanumab small amount data interpret
rather lot patient clear think tau amyloid differ role amyloid tell
trial amyloid alzheim diseas want
alzheim trial occur earli diseas cours pretti much plateau
lot growth amyloid cours diseas also good marker plaqu clear antibodi
show clear plaqu talk donanemab
aducanumab realli relat symptom diseas correl region brain
amyloid region brain degener lead symptom peopl amyloid
necessarili sever peopl less amyloid kind marker
tau hand right part brain link degener amount tau link
sever symptom given patient given region given point time follow patient
time watch tau level spread watch degener tau lot promis use
surrog endpoint efficaci make link huge power trial everyon get tau
imag multipl time point think glimmer publish trial way go
drug effect effect reduc either directli downstream spread tau thu
spread neurodegener gener heavili invest think best path forward
acceler regulatori approv would signal cognit function back robust biomark
evid slow rate neurodegener feel like good data packag someon
page
wolf product like flortaucipir hidden commerci opportun think
alzheim multi-million patient diseas everyon go get scan guess
evolv point like mention go watch tau level go
set baselin watch serial time guy space multipl area
amyloid imag agent tau imag tau serum level well revenu stream
think compani could meaning
dr skovronski know cours time hope amyloid imag would
import revenu stream saw illustr challeng face diagnost
absenc therapeut payer unwil reimburs promin would say work
coverag evid develop ten thousand patient gotten access
commerci opportun therapeut suggest could chang seen
part diagnost environ therapeut payer switch see diagnost
unnecessari cost way save money make sure treat right patient
wast money treat wrong patient environ could see interest imag
biomark hope come pass revenu mean great
therapeut right thing patient scienc advanc time see
commerci opportun initi think around tau imag modest around
support research patient defin set therapeut group game changer
wolf shift donanemab also refer think lead ad asset point
phase wrap around end year degre antidrug antibodi ada
earlier trial one discontinu high ada gener hear good thing
drug hear realli good plaqu buster better aducanumab hear may caus
less aria well could best-in-class molecul potenti least buzz talk
ada whether problem
dr skovronski definit ada immunogen antibodi reason fulli understand
patient saw nearli everyon gener immun respons typic safeti
concern although data seen smaller number patient lower dose antidrug
antibodi affect pk donanemab end use high dose good news limit cours
dose could adequ clear plaqu base data stay clear plaqu grow back
reason time cours path forward pursu sub-optimal
antidrug antibodi modestli chang version appar solv
immunogen issu look good next gener without issu sometim
futur swap cours work even immunogen still attract product bring
patient quickli possibl
wolf lot question would love ask area let shift coupl
diseas area start oncolog want ask collabor innov year
ago call describ limit opportun downstream lot
posit data set non-squam lung squamou lung recent esophag
question ask recent call still get answer ex-u
head opportun take product world outsid china would
page
dr skovronski probabl give kind non-answ got earn call say
good antibodi clearli data come partner china tremend perform
would hope would commerci recept china strong like
think opportun rest world differ environ competit must
think care valu proposit anoth antibodi may scenario
could import other might kind thing think
wolf anoth oncolog question kra guy kra reason size trial still
exploratori across multipl tumor type patient think report earli recent
termin kra field safeti insight good
everyon els remain worrisom across class think differ kra drug
dr skovronski still earli comment program unfortun coronaviru situat
help privi anyth guess concern on-target
safeti off-target safeti typic uniqu molecul common issu small molecul
differ molecul differ safeti issu someth watch target valid remain
cours thought definit good target best monotherapi target see
data competitor think see like import combin partner
good target respect also mean time window less critic slam
dunk monotherapi drug fast get seiz opportun come
complic clinic scenario combin becom long game enabl competitor
nuanc think clinic paradigm
wolf let shift immunolog lebrikizumab came dermira acquisit four
phase trial read late class bit checker histori
fail studi asthma two lead compound chang hand quit bit
product came roch dermira view
probabl success similar armo acquisit spend billion
dollar make bet sens lilli spend annual bet worth make
also higher risk program view risk profil class go atop
dr skovronski risk lower much lower character armo time high-risk high-
reward bet lower risk also lower reward look phase two data look
care across dose outcom endpoint felt compel would work take point
asthma look data well think mechan work right dose right
patient stori atop derm seem clear give high degre confid alway
possibl surpris phase three think high-risk
wolf top hour let ask one final question compound
cover today wish would ask would like call special
think overlook next big thing lilli
page
dr skovronski number thing excit across therapeut area non-coval
btk inhibitor data present extraordinari potenti move quickli
huge impact patient excit talk weekli insulin
develop week basal insulin realli neat opportun patient suit product
earli develop novel approach immunolog checkpoint agonist turn immun
system excit coupl phase one earli phase two trial year
coupl novel mechan pain huge unmet medic need lot look
forward
end convers
page
